Today’s Research Reports on Trending Tickers: Catalyst Biosciences and Valeant Pharmaceuticals
Progress of the recent tax bill hit a snag on Thursday as two GOP Senators raised some concerns. All sectors closed down on Thursday dragging markets lower, with the Healthcare and Materials contributing most losses. The Dow Jones Industrial Average declined 0.31 percent to close at 24,508.66, while the S&P 500 Index fell 0.41 percent to close at 2,652.01. The Nasdaq Composite Index decreased 0.28 percent to close at 6,856.53.
“This market has been going in lockstep with the progress made in the tax bill,” said Art Hogan, chief market strategist at B. Riley FBR. “When you see bumps in the road, you’re going to get some volatility.”
RDI Initiates Coverage on:
Catalyst Biosciences, Inc.
Valeant Pharmaceuticals International, Inc.
Catalyst Biosciences stock jumped 11.45% Thursday, to close the day at $9.93. The stock recorded a trading volume of 906,254 shares, which was above its three months average volume of 274,937 shares. Traders were probably excited about appointment of Edward Williams to its board of directors. In the last year, Catalyst Biosciences shares have traded in a range of 3.11 – 21.30. The share price has gained 219.29% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $5.92 is greater than its 200-day moving average of $4.69. Shares of Catalyst Biosciences have gained roughly 110.38 percent in the past month and are up 1.83 percent year-to-date.
Access RDI’s Catalyst Biosciences, Inc. Research Report at:
On Thursday, shares in Valeant Pharmaceuticals International, Inc. recorded a trading volume of 53,350,230 shares, which was above the three months average volume of 15,289,912 shares. The stock ended the day 10.75% lower at 19.68. Traders were concerned as J. P. Morgan securities downgraded the stock to an “underweight” rating. The share price has gained 136.82% from its 52 week low with a 52 week trading range of 8.31 – 22.81. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $15.39 is greater than its 200-day moving average of $14.77. Shares of Valeant Pharmaceuticals have gained roughly 37.82 percent in the past month and are up 35.54 percent year-to-date.
Access RDI’s Valeant Pharmaceuticals International, Inc. Research Report at:
Our Actionable Research on Catalyst Biosciences, Inc. (NASDAQ:CBIO) and Valeant Pharmaceuticals International, Inc. (NYSE:VRX) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.